Format

Send to

Choose Destination
Otolaryngol Head Neck Surg. 2017 Apr;156(4_suppl):S76-S87. doi: 10.1177/0194599816632178.

Panel 6: Vaccines.

Author information

1
1 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven Connecticut, USA.
2
2 PATH, Seattle, Washington, USA.
3
3 Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
4
4 Saint Louis University School of Medicine, St Louis, Missouri, USA.
5
5 Lund University, Lund, Sweden.
6
6 University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
7
7 University of Texas Medical Branch, Galveston, Texas, USA.
8
8 Boston University School of Medicine, Boston, Massachusetts, USA.
9
9 University at Buffalo, The State University of New York, Buffalo, New York, USA.

Abstract

Objective To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources PubMed database of the National Library of Science. Review Methods We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.

KEYWORDS:

Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumoniae; children; otitis media; vaccines

PMID:
28372533
PMCID:
PMC5505493
DOI:
10.1177/0194599816632178
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center